Our Approach
“Someday perhaps it will turn out to be one of the ironies of nature that cancer, responsible for so many deaths, should be so indissolubly connected with life.”
Charles Oberling (1946)
Company technology is based on interpretation of the malignant transformation in the interconnection and interdependence with the deficiency of tissues (functions) and the processes that underlie cellular senescence and reprogramming.
This approach will result in the prevention of cancer in healthy people and to effective, recurrence-free treatment in cancer patients. The theoretical ground of the proposed concept is detailed in several authors peer reviewed publications. To stop cancer, it is enough to induce complete immune tolerance toward early embryonic antigens. This will lead to rejuvenation instead of carcionogenesis.
Testing company reprogramming formula (RF*) in mice with spontaneous liver tumor (whole body imaging of tumor staining with vital dye).
